Recent Updates
Recently added Catalysts

Fasedienol

Phase 3

Social Anxiety Disorder | Small molecule | Psychiatry |Vistagen Therapeutics, Inc.|Last Updated: May 22, 2026

Target and mechanism

ModalitySmall molecule

Also known as Fasedienol Nasal Spray

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment238

FDA Designations

No designations recorded

Clinical trial landscape

Fasedienol · 2 trials · 2 indications

Phase 3 2
NCT06615557Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Social Anxiety Disorder (SAD)
ACTIVE NOT_RECRUITING238 Analytics
NCT06358651Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Social Anxiety Disorder
ACTIVE NOT_RECRUITING238 Analytics
PHASE3ACTIVE NOT_RECRUITING
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Social Anxiety Disorder (SAD)Unlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
Social Anxiety DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Subjective Units of Distress Scale (SUDS)
7 days (Visit 2 to Visit 3)

The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).

Secondary Endpoints

Global Impression Scale of Improvement (CGI-I)
7 days (Visit 2 to Visit 3)
Patient Global Impression of Change (PGI-C)
7 days (Visit 2 to Visit 3)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Fasedienol Nasal SprayEXPERIMENTAL -
Placebo Nasal SprayEXPERIMENTAL -

Interventions

NameTypeDescription
Fasedienol Nasal SprayDRUGNasal spray delivered 20 minutes before the PSC
Placebo Nasal SprayDRUGNasal spray delivered 20 minutes before the PSC
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites26

Inclusion Criteria: * Written informed consent provided prior to conducting any study-specific assessment. * Male and female adults, 18 through 65 years of age, inclusive. * Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirmed ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Fasedienol

What is Fasedienol used for?

Fasedienol is an investigational small molecule nasal spray being developed for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). It is currently in Phase 3 clinical development and has not been approved by the FDA.

Who makes Fasedienol?

Fasedienol is being developed by Vistagen Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VTGN. The company is conducting Phase 3 clinical trials for this investigational nasal spray.

What phase is Fasedienol in?

Fasedienol is in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 3 trials, PALISADE-3 and PALISADE-4, are currently active but not recruiting participants.

What clinical trials is Fasedienol in?

Fasedienol is being studied in two Phase 3 clinical trials: PALISADE-3 (NCT06358651) and PALISADE-4 (NCT06615557). Both are randomized, double-blind, placebo-controlled studies enrolling 238 adults aged 18 years and older with Social Anxiety Disorder in the United States.

Is Fasedienol the same as Fasedienol Nasal Spray?

Yes, Fasedienol is also known as Fasedienol Nasal Spray. The drug is administered as a nasal spray and is being investigated for the acute treatment of anxiety in adults with Social Anxiety Disorder.